Sunday, March 6, 2022
Cancers are composed of millions of tumor cells with molecular changes that bestow upon them the ability to grow and spread. Prior to the genomic revolution of the mid-2000s, we knew little about the nature of these molecular changes, so winning the war on cancer was impossible.
In this public seminar, Dr. Jesse Boehm will discuss how technological revolutions of the past decade including genomics, CRISPR gene engineering, and patient engagement via social media, are now providing a roadmap to foster the success of cancer precision medicine, and how new forms of collaborative enterprises between formerly competitive organizations are templating new structural models for the scientific enterprise underpinning this cancer research revolution.
Dr. Jesse Boehm is the Chief Scientific Officer of Break Through Cancer and principal investigator at the Broad Institute of Harvard and MIT. His laboratory at MIT works on creating new patient-powered, open-source solutions to discover novel therapeutic targets for rare and underrepresented tumors.
Dr. Boehm received his undergraduate degree from MIT and his Ph.D. in cancer biology from the Dana-Farber Cancer Institute at Harvard Medical School. He grew up in Concord, attended CCHS and Hebrew school at Kerem Shalom, and now lives in Wellesley MA with his wife and two sons.